Vertex Pharmaceuticals has significantly outpaced the market in the past few decades. The company owes its performance to a well-defined strategy and its innovative abilities....
Vertex Pharmaceuticals is working on a therapy to treat diabetes. The latest data about that therapy's performance looks solid....
Amgen is much cheaper than Eli Lilly. Vertex Pharmaceuticals has several major growth drivers....
Gene editing utilizes enzymes that cut part of the DNA strand, allowing the insertion of replacement DNA. Several approaches to gene editing have been developed, the most well-known of which is CRISPR...
The FDA accepts Vertex's (VRTX) new drug application for vanza triple therapy for people living with cystic fibrosis aged six years and above. A decision is due on Jan 2, 2025....
One of the most important sectors in any country's economy is the biotech sector. Picking under-the-radar biotech stocks is easier said than done because we do not see immediate results....
With the technology sector taking over in 2024, now is a great time to consider the best breakout biotech stocks to buy. Investing in these companies can be risky yet extremely rewarding, with careful...
If you have some cash on hand to invest long term, there are plenty of stocks begging to be bought. Vertex expects several product launches even as its mainstay portfolio continues to drive profitabil...
The rare disease drug industry is fast-growing, while the music streaming space is also expanding at a rapid clip. Vertex is raking in profits from its cystic fibrosis drug franchise, but is also plan...
Vertex Pharmaceuticals could have multiple new blockbusters on the way. Viking Therapeutics is targeting two massive markets -- obesity and NASH....
A rare-disease drugmaker and a top pharmaceutical stock have what it takes to deliver solid returns over the long run. Vertex Pharmaceuticals' flagship business continues to expand market share and pr...